Related Experiment Videos

Statins and myocardial hypertrophy

Hironori Nakagami1, James K Liao

  • 1Vascular Medicine Research, Brigham and Women's Hospital and Harvard Medical School, Cambridge, Massachusetts 02139, USA.

Coronary Artery Disease
|July 9, 2004
PubMed

Insights

Statins, a cholesterol-lowering drug, can inhibit cardiac hypertrophy by blocking the activation of Rho GTPase proteins. This mechanism reduces oxidative stress and may prevent heart failure.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology

Background:

  • Cardiac hypertrophy is an adaptive heart response to pressure overload that can become maladaptive, leading to heart failure.
  • Statins are known to inhibit cardiac hypertrophy through mechanisms independent of cholesterol reduction.

Purpose of the Study:

  • To investigate the cholesterol-independent mechanisms by which statins inhibit cardiac hypertrophy.
  • To elucidate the role of Rho GTPase signaling and oxidative stress in statin-mediated inhibition of cardiac hypertrophy.

Main Methods:

  • The study focuses on the molecular mechanisms of statin action in cardiac hypertrophy.
  • Investigated the inhibition of Rho guanosine triphosphatase (GTPase) family members, specifically RhoA and Rac1, by statins.
  • Examined the role of Rac1 in reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and reactive oxygen species (ROS) production.

Main Results:

  • Statins inhibit the isoprenylation and activation of Rho GTPase proteins, including RhoA and Rac1.
  • Rac1 is essential for the function of NADPH oxidase, a key source of ROS in cardiovascular cells.
  • Statins' inhibition of Rac1-mediated oxidative stress contributes to their anti-hypertrophic effects.

Conclusions:

  • Statins exert protective effects against cardiac hypertrophy via cholesterol-independent pathways.
  • Inhibition of Rho GTPase signaling and subsequent reduction in oxidative stress are critical mechanisms for statin efficacy in preventing maladaptive cardiac remodeling.
  • These findings highlight statins as potential therapeutic agents for managing conditions associated with cardiac hypertrophy and heart failure.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...